Gilead shuffles CV execs as part of CV Therapeutics integration
Biopharmaceutical firm Gilead Sciences, as part of the ongoing integration of CV Therapeutics, has announced changes to its cardiovascular research and development (R&D) organization leadership.
Louis G. Lange, MD, PhD, has decided to assume a part-time position at the Foster City, Calif.-based Gilead and will therefore be transitioning from his role as executive vice president of CV Therapeutics.
With this transition, Gilead said its cardiovascular R&D organization will report to Norbert Bischofberger, PhD, executive vice president of R&D and chief scientific officer at Gilead. Luiz Belardinelli, MD, senior vice president of CV Therapeutics, will serve as therapeutic area head for cardiovascular therapeutics, based in Palo Alto, Calif., and reporting to Bischofberger.
Louis G. Lange, MD, PhD, has decided to assume a part-time position at the Foster City, Calif.-based Gilead and will therefore be transitioning from his role as executive vice president of CV Therapeutics.
With this transition, Gilead said its cardiovascular R&D organization will report to Norbert Bischofberger, PhD, executive vice president of R&D and chief scientific officer at Gilead. Luiz Belardinelli, MD, senior vice president of CV Therapeutics, will serve as therapeutic area head for cardiovascular therapeutics, based in Palo Alto, Calif., and reporting to Bischofberger.